According to the Wall Street Journal – the company will evaluate use of the active ingredient in the weedkiller after a judge rejected its plan to resolve future lawsuits from cancer patients.
Bayer AG said it will evaluate whether to continue using the active ingredient in its popular Roundup weedkiller in the residential U.S. market, in the wake of a court setback Wednesday in the company’s efforts to limit future liability over whether the product causes cancer.